Research Group
Breast and Gynecologic Cancer
Sponsor
Fred Hutchinson Cancer Center
Status
Terminated
NCT ID
NCT03051516
This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill tumor cells and decrease the chance of vulvar or anal lesions to progress or come back.
Intervention
Recombinant Human Papillomavirus Nonavalent Vaccine, Placebo Administration, Questionnaire Administration, Laboratory Biomarker Analysis
Condition
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Investigators
Anna Wald